APA (7th ed.) Citation

Chen, D., Liu, Z., Wang, G., Tu, M., Yang, F., Jiang, C., . . . Su, X. The clinical benefits of [18F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: Comparison of [18F]FDG PET/CT. BMC.

Chicago Style (17th ed.) Citation

Chen, Donghe, Zhenfeng Liu, Guolin Wang, Mengjiao Tu, Fei Yang, Chunting Jiang, Kui Zhao, and Xinhui Su. The Clinical Benefits of [18F]AlF-NOTA-octreotide PET/CT in Staging and Restaging Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Comparison of [18F]FDG PET/CT. BMC.

MLA (9th ed.) Citation

Chen, Donghe, et al. The Clinical Benefits of [18F]AlF-NOTA-octreotide PET/CT in Staging and Restaging Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Comparison of [18F]FDG PET/CT. BMC.